JP2022527499A5 - - Google Patents

Info

Publication number
JP2022527499A5
JP2022527499A5 JP2021557941A JP2021557941A JP2022527499A5 JP 2022527499 A5 JP2022527499 A5 JP 2022527499A5 JP 2021557941 A JP2021557941 A JP 2021557941A JP 2021557941 A JP2021557941 A JP 2021557941A JP 2022527499 A5 JP2022527499 A5 JP 2022527499A5
Authority
JP
Japan
Prior art keywords
cancer
pharmaceutical product
mutations
product according
poziotinib
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021557941A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022527499A (ja
JP7700043B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/025478 external-priority patent/WO2020205632A1/en
Publication of JP2022527499A publication Critical patent/JP2022527499A/ja
Publication of JP2022527499A5 publication Critical patent/JP2022527499A5/ja
Application granted granted Critical
Publication of JP7700043B2 publication Critical patent/JP7700043B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021557941A 2019-03-29 2020-03-27 Her2エクソン21挿入を有するがん細胞に対する抗腫瘍活性を有する化合物 Active JP7700043B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962826758P 2019-03-29 2019-03-29
US62/826,758 2019-03-29
PCT/US2020/025478 WO2020205632A1 (en) 2019-03-29 2020-03-27 Compounds with anti-tumor activity against cancer cells bearing her2 exon 21 insertions

Publications (3)

Publication Number Publication Date
JP2022527499A JP2022527499A (ja) 2022-06-02
JP2022527499A5 true JP2022527499A5 (cg-RX-API-DMAC7.html) 2023-03-30
JP7700043B2 JP7700043B2 (ja) 2025-06-30

Family

ID=72666271

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021557941A Active JP7700043B2 (ja) 2019-03-29 2020-03-27 Her2エクソン21挿入を有するがん細胞に対する抗腫瘍活性を有する化合物

Country Status (13)

Country Link
US (1) US12629375B2 (cg-RX-API-DMAC7.html)
EP (1) EP3946632A4 (cg-RX-API-DMAC7.html)
JP (1) JP7700043B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210145161A (cg-RX-API-DMAC7.html)
CN (1) CN113766955A (cg-RX-API-DMAC7.html)
AU (1) AU2020256119A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021019376A2 (cg-RX-API-DMAC7.html)
CA (1) CA3132834A1 (cg-RX-API-DMAC7.html)
IL (1) IL286576A (cg-RX-API-DMAC7.html)
MX (1) MX2021011925A (cg-RX-API-DMAC7.html)
PH (1) PH12021552110A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202109531UA (cg-RX-API-DMAC7.html)
WO (1) WO2020205632A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12629375B2 (en) 2019-03-29 2026-05-19 Board Of Regents, The University Of Texas System Compounds with anti-tumor activity against cancer cells bearing HER2 exon 21 insertions
JP7709384B2 (ja) * 2019-04-17 2025-07-16 ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム チロシンキナーゼ阻害剤耐性egfr変異を有するがんに対する化合物
UY39593A (es) * 2020-12-29 2022-07-29 Spectrum Pharmaceuticals Inc Tratamiento para tumores sólidos malignos
EP4568994A1 (en) * 2022-08-09 2025-06-18 Heligenics, Inc. Method for evaluating clinical relevance of genetic variance

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19911509A1 (de) 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE10042058A1 (de) 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
WO2005026150A1 (en) 2003-09-16 2005-03-24 Astrazeneca Ab Quinazoline derivatives as tyrosine kinase inhibitors
DE10349113A1 (de) 2003-10-17 2005-05-12 Boehringer Ingelheim Pharma Verfahren zur Herstellung von Aminocrotonylverbindungen
MX2007009265A (es) 2005-02-04 2007-09-07 Boehringer Ingelheim Int Uso de inhibidores de tirosina quinasa para el tratamiento de rinosinusitis cronica.
CA2601936C (en) 2005-02-24 2014-06-17 Amgen Inc. Epidermal growth factor receptor mutations
CN101351563A (zh) 2005-10-05 2009-01-21 阿斯利康(英国)有限公司 用于预测或监测病人对于ErbB受体药物的响应的方法
TWI377944B (en) 2007-06-05 2012-12-01 Hanmi Holdings Co Ltd Novel amide derivative for inhibiting the growth of cancer cells
PE20100252A1 (es) 2008-06-06 2010-04-12 Boehringer Ingelheim Int Nuevas formulaciones farmaceuticas solidas que comprenden dimaleato de 4-[(3-cloro-4-fluorofenil) amino]-6-{[4-(n,n-dimetilamino)-1-oxo-2-buten-1-il] amino}-7-((s)-tetrahidrofuran-3-iloxi)-quinazolina
KR101217526B1 (ko) * 2010-06-11 2013-01-02 한미사이언스 주식회사 아마이드 유도체 또는 이의 약학적으로 허용 가능한 염을 포함하는 약제학적 조성물
US8828391B2 (en) 2011-05-17 2014-09-09 Boehringer Ingelheim International Gmbh Method for EGFR directed combination treatment of non-small cell lung cancer
KR101317809B1 (ko) 2011-06-07 2013-10-16 한미약품 주식회사 암세포의 성장을 억제하는 아마이드 유도체 및 비금속염 활택제를 포함하는 약학 조성물
US9738935B2 (en) 2011-11-10 2017-08-22 Roche Molecular Systems, Inc. Complex mutations in the epidermal growth factor receptor kinase domain
EP3603678A3 (en) * 2011-12-14 2020-07-29 The Board of Regents of the University of Texas System Collateral gene inactivation biomarkers and targets for cancer therapy
AU2013355260B2 (en) 2012-12-04 2019-07-25 Caris Mpi, Inc. Molecular profiling for cancer
US20180057603A1 (en) 2013-08-09 2018-03-01 The Trustees Of The University Of Pennsylvania Combination of IFN-gamma with Anti-ERBB Antibody for the Treatment of Cancers
TWI603971B (zh) 2013-08-22 2017-11-01 Taiho Pharmaceutical Co Ltd Novel quinoline substituted compounds
EP3699589A1 (en) 2014-12-12 2020-08-26 Celcuity Inc. Methods of measuring erbb signaling pathway activity to diagnose and treat cancer patients
CN107250108B (zh) 2015-02-05 2020-11-27 特尔诺沃有限公司 用于治疗癌症的irs/stat3双重调节剂与抗癌剂的组合
CN107530434A (zh) 2015-04-23 2018-01-02 免疫医疗有限公司 非小细胞肺癌egfr突变阳性的联合疗法
US10308658B2 (en) 2015-10-19 2019-06-04 Sunshine Lake Pharma Co., Ltd. Salt of EGFR inhibitor, crystalline form and uses thereof
EP3458064A1 (en) 2016-05-18 2019-03-27 Boehringer Ingelheim International GmbH Anticancer combination therapy
CN109789204A (zh) * 2016-05-31 2019-05-21 雀巢产品技术援助有限公司 基于her2和her3通路亚型选择乳癌患者药物疗法的方法
BR112019010020A2 (pt) 2016-11-17 2019-08-20 Univ Texas compostos com atividade anti-tumoral contra células cancerosas contendo mutações de egfr ou her2 exon 20
EP3585389A4 (en) 2017-02-22 2020-12-23 G1 Therapeutics, Inc. EGFR-CAUSED CANCER TREATMENT WITH LESS SIDE EFFECTS
WO2018213770A1 (en) 2017-05-19 2018-11-22 Regents Of The University Of Minnesota Therapeutic methods
CA3076915A1 (en) 2017-09-27 2019-04-04 AI Therapeutics, Inc. Therapeutic methods relating to hsp90 inhibitors
KR20190054826A (ko) 2017-11-14 2019-05-22 한미약품 주식회사 암의 포지오티닙 치료에 대한 반응을 나타내는 바이오마커 및 그의 용도
JP7386174B2 (ja) 2018-03-27 2023-11-24 ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム Her2エクソン19変異を有するがん細胞に対する抗腫瘍活性を有する化合物
US20210235688A1 (en) 2018-04-19 2021-08-05 Board Of Regents, The University Of Texas System Methods for measuring and stabilizing stat3 inhibitors
SG11202012064PA (en) 2018-06-25 2021-01-28 Spectrum Pharmaceuticals Inc Combination of poziotinib with cytotoxic agent and/or other molecularly targeted agent and use thereof
CA3098204A1 (en) 2018-06-25 2020-01-02 Spectrum Pharmaceuticals, Inc. Poziotinib combinations with an anti-her1, her2 or her4 antibody and methods of use thereof
KR20210066819A (ko) 2018-09-04 2021-06-07 레인 세러퓨틱스 인코포레이티드 Her-유도 암을 치료 또는 예방하기 위한 화합물, 조성물 및 방법
KR20210107023A (ko) * 2018-12-21 2021-08-31 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 암 치료를 위한 조합 요법
WO2020150208A1 (en) 2019-01-14 2020-07-23 Board Of Regents, The University Of Texas System Compositions and methods for treating cancer using il-17 signaling inhibitors and immune checkpoint inhibitors
US12679855B2 (en) 2019-01-27 2026-07-14 Board Of Regents, The University Of Texas System Inhibitors of the enzyme enolase for precision oncology
WO2020172485A1 (en) 2019-02-22 2020-08-27 Board Of Regents, The University Of Texas System Methods of using imipridones
MX2021010265A (es) 2019-02-26 2021-09-23 Janssen Biotech Inc Terapias de combinacion y estratificacion de pacientes con anticuerpos anti-egfr/c-met biespecificos.
US20200299783A1 (en) 2019-03-18 2020-09-24 Board Of Regents, The University Of Texas System Molecular signature for selecting lymphoma patients for treatment with ibrutinib
WO2020198633A1 (en) 2019-03-27 2020-10-01 Board Of Regents, The University Of Texas System Nuclear-derived exosomes and methods of use thereof
WO2020205646A2 (en) 2019-03-29 2020-10-08 Board Of Regents, The University Of Texas System Small molecule parg inhibitors and methods of use thereof
US12629375B2 (en) 2019-03-29 2026-05-19 Board Of Regents, The University Of Texas System Compounds with anti-tumor activity against cancer cells bearing HER2 exon 21 insertions
US20220143023A1 (en) 2019-03-29 2022-05-12 Board Of Regents, The University Of Texas System Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20 insertions
JP7709384B2 (ja) 2019-04-17 2025-07-16 ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム チロシンキナーゼ阻害剤耐性egfr変異を有するがんに対する化合物
JP7822597B2 (ja) 2019-04-17 2026-03-03 ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム チロシンキナーゼ阻害剤耐性egfr変異を有するがん細胞に対する抗腫瘍活性を有する化合物
KR102477643B1 (ko) * 2019-05-09 2022-12-13 주식회사 엘지에너지솔루션 전기화학소자용 분리막 및 이를 포함하는 전기화학소자
WO2020251965A1 (en) 2019-06-10 2020-12-17 Board Of Regents, The University Of Texas System Combinatorial therapy targeting parp1 and rtk
US20220356467A1 (en) 2019-06-25 2022-11-10 Board Of Regents, The University Of Texas System Methods for duplex sequencing of cell-free dna and applications thereof

Similar Documents

Publication Publication Date Title
JP2022529945A5 (cg-RX-API-DMAC7.html)
JP2022529016A5 (cg-RX-API-DMAC7.html)
JP2022527788A5 (cg-RX-API-DMAC7.html)
JP2020502059A5 (cg-RX-API-DMAC7.html)
US11291667B2 (en) Combination therapy involving diaryl macrocyclic compounds
Ponti et al. BRAF, NRAS and C-KIT advanced melanoma: clinico-pathological features, targeted-therapy strategies and survival
JP2021517894A5 (cg-RX-API-DMAC7.html)
JP2019533670A5 (cg-RX-API-DMAC7.html)
WO2025179058A1 (en) Pyridopyrimidine derivative as kras g12c inhibitor for the treatment of brain metastasis
JP2021519306A5 (cg-RX-API-DMAC7.html)
JP2019532011A5 (cg-RX-API-DMAC7.html)
WO2017129094A1 (zh) 一种egfr/her2受体酪氨酸激酶抑制剂在制备治疗her2突变癌症药物中的用途
RU2020134932A (ru) Соединения с противоопухолевой активностью против раковых клеток, несущих мутации в экзоне 19her2
CN110840892A (zh) 酪氨酸激酶抑制剂与cdk4/6抑制剂联合在制备预防或治疗肿瘤疾病的药物中的用途
CN117919234A (zh) 一种萘酰胺化合物治疗耐药性肿瘤的用途
JP2022515128A5 (cg-RX-API-DMAC7.html)
WO2021023204A1 (zh) Cdk4/6抑制剂与多靶点酪氨酸激酶抑制剂联合在制备治疗肿瘤的药物中的用途
US20230241081A1 (en) Method for Treating Melanoma
CN113840608B (zh) Cdk4/6抑制剂与vegfr抑制剂联合在制备治疗肿瘤的药物中的用途
JP7334194B2 (ja) Tp53突然変異状態及び高頻度突然変異状態に基づくがん治療法
Grellety et al. A clinical case of invasive lobular breast carcinoma with ERBB2 and CDH1 mutations presenting a dramatic response to anti-HER2-directed therapy
US20130005747A1 (en) Method for selecting a cancer therapy
Higashi et al. A Case of BRAF-V600E-Positive Pulmonary Pleomorphic Carcinoma Successfully Treated With Dabrafenib and Trametinib Administered via a Percutaneous Endoscopic Gastrojejunostomy Tube for Ileus Caused by Small Intestinal Metastasis
Nemtsova et al. Molecular classifications of gastric cancer and their clinical potential
WO2021104341A1 (zh) 一种取代丁烯酰胺的应用